<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mutations in LMNA, the gene that encodes A-type lamins, cause multiple diseases including <z:mpath ids='MPATH_554'>dystrophies</z:mpath> of the skeletal muscle and fat, <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo>, and <z:e sem="disease" ids="C1261128,C0009207" disease_type="Disease or Syndrome" abbrv="">progeria-like syndromes</z:e> (collectively termed laminopathies) </plain></SENT>
<SENT sid="1" pm="."><plain>Reduced A-type lamin function, however, is most commonly associated with skeletal muscle <z:mpath ids='MPATH_554'>dystrophy</z:mpath> and <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> rather than <z:hpo ids='HP_0009125'>lipodystrophy</z:hpo> or <z:e sem="disease" ids="C0033300" disease_type="Disease or Syndrome" abbrv="">progeria</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The mechanisms underlying these diseases are only beginning to be unraveled </plain></SENT>
<SENT sid="3" pm="."><plain>We report that mice deficient in Lmna, which corresponds to the human gene LMNA, have enhanced mTORC1 (mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> complex 1) signaling specifically in tissues linked to pathology, namely, cardiac and skeletal muscle </plain></SENT>
<SENT sid="4" pm="."><plain>Pharmacologic reversal of elevated mTORC1 signaling by <z:chebi fb="0" ids="9168">rapamycin</z:chebi> improves cardiac and skeletal muscle function and enhances survival in mice lacking A-type lamins </plain></SENT>
<SENT sid="5" pm="."><plain>At the cellular level, <z:chebi fb="0" ids="9168">rapamycin</z:chebi> decreases the number of myocytes with abnormal desmin accumulation and decreases the amount of desmin in both muscle and cardiac tissue of Lmna(-/-) mice </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, inhibition of mTORC1 signaling with <z:chebi fb="0" ids="9168">rapamycin</z:chebi> improves defective autophagic-mediated degradation in Lmna(-/-) mice </plain></SENT>
<SENT sid="7" pm="."><plain>Together, these findings point to aberrant mTORC1 signaling as a mechanistic component of laminopathies associated with reduced A-type lamin function and offer a potential therapeutic approach, namely, the use of <z:chebi fb="0" ids="9168">rapamycin</z:chebi>-related mTORC1 inhibitors </plain></SENT>
</text></document>